Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcellx, Inc. - Common Stock (NQ: ACLX )

77.58 +0.79 (+1.03%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 267,611
Open 76.63
Bid (Size) 31.03 (2)
Ask (Size) 84.00 (1)
Prev. Close 76.79
Today's Range 75.53 - 77.94
52wk Range 47.88 - 107.37
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
In-Depth Examination Of 14 Analyst Recommendations For Arcellx
Via Benzinga
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
The companies held competing events on Sunday to discuss their multiple myeloma treatments. 
Via Investor's Business Daily

Performance

YTD
+38.17%
+38.17%
1 Month
-13.23%
-13.23%
3 Month
-8.30%
-8.30%
6 Month
+44.58%
+44.58%
1 Year
+33.78%
+33.78%

More News

Read More
14 Analysts Have This To Say About Arcellx
Via Benzinga
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
Via Benzinga
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition
From Arcellx, Inc.
Via Business Wire
Analyst Expectations For Arcellx's Future
Via Benzinga
Navigating 7 Analyst Ratings For Arcellx
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Arcellx
Via Benzinga
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights
From Arcellx, Inc.
Via Business Wire
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study
From Arcellx, Inc.
Via Business Wire
4 Analysts Assess Arcellx: What You Need To Know
Via Benzinga
Assessing Arcellx: Insights From 7 Financial Analysts
Via Benzinga
Decoding 8 Analyst Evaluations For Arcellx
Via Benzinga
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Arcellx Provides Second Quarter 2024 Financial Results and Business Updates
From Arcellx, Inc.
Via Business Wire
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
Via InvestorPlace
Exposures Product Safety
Arcellx Stock Earns Relative Strength Rating Upgrade
Via Investor's Business Daily
The Latest Analyst Ratings For Arcellx
Via Benzinga
Expert Ratings For Arcellx
Via Benzinga
Analyst Expectations For Arcellx's Future
Via Benzinga
7 Biotech Stocks to Put on Your Breakthrough Radar
Via InvestorPlace
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
From Arcellx, Inc.
Via Business Wire
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
From Gilead Sciences, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.